Legal Battle Over E-Cigarette Ban: Constitutionality Challenge in Kentucky

Regulations by 2FIRSTS.ai
Jul.09.2024
Legal Battle Over E-Cigarette Ban: Constitutionality Challenge in Kentucky
Kentuckylantern reported on July 8 that Judge Thomas Wingate heard a case questioning the constitutionality of a law banning e-cigarette sales.

According to Kentucky Lantern's report on July 8th, Judge Thomas Wingate of the Franklin Circuit Court presided over a case on Monday (the 8th) questioning the constitutionality of a law banning the sale of certain e-cigarette products.

 

The defendants in the case, Allyson Taylor, the Director of the Alcohol Beverage Control Board in the state of Kentucky, and Secretary of State Michael Adams, have filed a motion to dismiss the case.

 

If Governor Whitaker approves this request, the plaintiffs, including the Kentucky E-Cigarette Retailers Association, the Kentucky Cannabis Association, and four e-cigarette sales shops, will appeal the decision. The plaintiffs have also filed a request for the court to make a judgment. However, the case is far from being resolved. Whitaker stated that he will need "some time" to review the matter.

 

This lawsuit centers around House Bill 11, which was passed in the legislative assembly in 2024. Supporters of the bill argue that it is a way to curb the use of e-cigarettes by minors by restricting the sale of "authorized products" or products that have obtained a "safe harbor certification" based on guidelines from the US FDA. Opponents argue that this will harm small businesses and lead to monopolies by large retailers.

 

According to records from the Legislative Ethics Commission, the tobacco giant Altria (previously known as Philip Morris) has lobbied for legislation in Kentucky and other states. The company has also entered the e-cigarette market, selling a variety of FDA-approved e-cigarette products.

 

Greg Troutman, the lawyer for the Kentucky Smoke Free Association, expressed to the judge on Monday that one of the many issues with the new law is how it defines "vapor products" and "other substances," lumping e-cigarettes and marijuana products together. He believes that this combination makes the law too broad and arbitrary, and it does not adhere to the constitution.

 

Troutman argued that the title of the bill, "The Nicotine Products Act," does not accurately represent the content of the legislation.

 

Assistant Attorney Lindsey Keiser rebutted by saying that headlines do not need to fully summarize the content of the bill.

 

It is a long-established fact that headlines do not need to include all the items contained in the bill.

 

The limited number of FDA approvals signifies concerns about these products. Therefore, Kentucky has ample reason to say, "If the FDA is only approving such a limited number, we should also strive to minimize the number approved.

 

Trotman argued that the state's regulations are flawed because they are built upon a flawed federal system.

 

Our state program was established before the federal program, which has itself been found arbitrary by at least two federal courts.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Product | Pouchless Oral Nicotine NAKD Nicotine Pods Launch with “Garlic-Clove” Shape and Structural Design Drawing Attention
Product | Pouchless Oral Nicotine NAKD Nicotine Pods Launch with “Garlic-Clove” Shape and Structural Design Drawing Attention
NAKD nicotine pods have been launched overseas with a pouchless solid-pellet design, featuring a “garlic clove–like” appearance that is smaller than traditional nicotine pouches. Made from compostable materials and positioned around instant nicotine release, the product is developed by Norwegian brand Den Norske Snusfabrikken and is already available in several European markets.
Nov.18 by 2FIRSTS.ai
Philip Morris USA Reaches $66M Settlement With Washington State Over MSA Payment Dispute
Philip Morris USA Reaches $66M Settlement With Washington State Over MSA Payment Dispute
Philip Morris USA has reached a settlement with Washington State and agreed to pay $66 million to resolve disputes over annual payments under the 1998 Master Settlement Agreement (MSA) for the period 2005–2015.
Nov.04 by 2FIRSTS.ai
Smoore: Profit Growth Gradually Improving, Fourth Quarter Shows Promise — A 2Firsts Reader Submission
Smoore: Profit Growth Gradually Improving, Fourth Quarter Shows Promise — A 2Firsts Reader Submission
Smoore released its financial results for the third quarter of 2025.A reader submitted to 2Firsts, noting that Smoore’s declining profit margin was mainly due to the substantial upfront investment in its new heated tobacco products, the relatively low margins of vaping devices, and price reductions resulting from product iterations in the European atomization market.as product structure adjustments near completion, the company’s profit growth is expected to further rebound in the fourth quart.
Oct.13
BAT appoints Matthew Wright as Independent Non-Executive Director, effective November 1, 2025
BAT appoints Matthew Wright as Independent Non-Executive Director, effective November 1, 2025
Matthew Wright appointed as independent non-executive director of British American Tobacco, effective November 1, bringing extensive international executive experience.
Oct.15 by 2FIRSTS.ai
SKE Partners with 7-Eleven Korea, Placing Its Products in Over 5,700 Stores
SKE Partners with 7-Eleven Korea, Placing Its Products in Over 5,700 Stores
According to an SKE release published on PR Newswire, the company is expanding its presence in the Korean market through convenience store and specialty retail channels. SKE has partnered with 7-Eleven Korea, placing its products in more than 5,700 stores nationwide, and is also working with OG9’s offline retail and B2B distribution network. On the product side, SKE is focusing on promoting the Crystal Bar TB1000 and Cloud Zero in Korea.
Nov.19 by 2FIRSTS.ai
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.
Oct.20 by 2FIRSTS.ai